Relapse common after pulmonary sarcoidosis treatment changes
Review finds relapse definitions varied widely across 51 studies
Written by |
Nearly 4 in 10 people with pulmonary sarcoidosis had a relapse after reducing or stopping treatment, according to a review of more than 50 published studies.
Most studies with timing data reported relapses occurring within 1.5 years of reducing or discontinuing treatment. Black patients and those with more advanced lung disease were at significantly greater risk, while combination treatment and longer corticosteroid treatment were associated with trends toward fewer relapses.
Relapse definitions varied widely
The findings, however, show that fewer than half of the studies provided an explicit definition of relapse, highlighting considerable variation in how relapses are identified and reported across studies.
“Our findings underscore the need for international consensus on relapse definitions and standardized relapse detection approaches to strengthen future clinical trials and optimize long-term disease management,” researchers wrote in the study, “Prevalence of relapse in pulmonary sarcoidosis: A systematic review and meta-analysis,” published in Respiratory Medicine.
Sarcoidosis is marked by inflammation and the formation of small clumps of inflammatory cells, called granulomas, in different tissues and organs. It most commonly affects the lungs, where it is known as pulmonary sarcoidosis and can cause symptoms such as shortness of breath and cough.
While about one-third of people with pulmonary sarcoidosis go into remission within two to three years without treatment, many develop persistent or relapsing disease that requires long-term immunosuppressive therapy.
Because prolonged use of these therapies, particularly corticosteroids, can cause serious side effects, treatment is often reduced or discontinued once the disease is under control. However, reducing or stopping treatment may trigger a relapse, broadly defined as worsening symptoms, imaging findings, or lung function.
Previous studies have reported widely varying relapse rates, making it difficult to estimate how often relapses occur and identify which patients are at greatest risk.
To address this, researchers in India conducted a systematic review and meta-analysis of 51 studies involving 6,093 patients with pulmonary sarcoidosis, published between 1961 and January 2026.
Nearly 4 in 10 patients relapsed
Among 3,682 patients who were followed after treatment reduction or discontinuation, 1,442 relapses were reported, corresponding to a pooled relapse prevalence of 0.39. This means that 39%, or about 4 out of every 10 patients, had a relapse after reducing or stopping treatment. Relapse rates in individual studies varied widely, however, ranging from 10% to 88%.
In the 19 studies that reported how long it took for relapses to occur, the median time to relapse was about 10.5 months, but the timing also varied considerably in individual studies. Nearly two-thirds of these studies reported relapses occurring within 1.5 years, and 84% reported them within three years.
Only 23 studies (45%) provided an explicit definition of relapse. Among them, 39% defined relapse using clinical criteria alone, while the remaining studies also considered imaging findings, lung function tests, or biomarkers. However, the type of definition used did not significantly affect the estimated relapse rate.
A person’s age and sex also did not affect the likelihood of experiencing a relapse. However, in studies that reported race, Black patients were about 2.5 times more likely to experience a relapse than White patients. Patients with more advanced lung disease on X-rays also had a significantly higher risk of relapse than those with milder disease. Whether sarcoidosis affected only the lungs or multiple organs did not appear to influence the risk of relapse.
Corticosteroids alone were the most common treatment approach, used in 73% of the studies. Steroid-sparing agents were used in 14%, while another 14% evaluated combination treatment. Although combination therapy was associated with a lower relapse prevalence than either approach alone, the difference was not statistically significant.
Treatment duration may matter
Patients treated with corticosteroids for more than 1.5 years also tended to have fewer relapses than those treated for a shorter period, but treatment duration alone did not fully explain differences in relapse risk.
Researchers also examined whether certain study characteristics could explain differences in relapse rates. The only factor that significantly influenced the findings was study design: prospective studies, which follow patients over time, reported lower relapse rates than retrospective studies, which look back at existing medical records.
“Collectively, these findings suggest that variations in relapse prevalence are driven not solely by methodological quality but also by clinical differences across populations, treatment strategies, relapse assessment practices, and follow-up durations,” the researchers concluded.
Leave a comment
Fill in the required fields to post. Your email address will not be published.